Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women.
Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women.
复制标题
DOI：
10.1186/1477-5751-5-11
复制
发表时间：
2006-08-14
期刊：
影响因子：
--
通讯作者：
Koebnick, Corinna
中科院分区：
文献类型：
--
作者：
Weickert, Martin O;Reimann, Manja;Otto, Barbel;Hall, Wendy L;Vafeiadou, Katherina;Hallund, Jesper;Ferrari, Marika;Talbot, Duncan;Branca, Francesco;Bugel, Susanne;Williams, Christine M;Zunft, Hans-Joachim;Koebnick, Corinna
大豆异黄酮显示出与雌二醇的结构和功能相似性。现有的数据表明，雌二醇和雌二醇样成分可能与肠道“饱腹激素”，如肽YY（PYY）和生长激素释放肽相互作用，从而影响体重。在一项随机、双盲、安慰剂对照、交叉试验中，34名健康绝经后妇女（59 ± 6岁，BMI：24.7 ± 2.8 kg/m2）食用富含维生素B1的谷物棒（50 mg维生素B1/天;染料木黄酮与大豆苷元的比例为2：1）或非富含维生素B1的对照棒8周（洗脱期：8周）。其中17名受试者被归类为雌马酚生产者。在基线和每个干预组的4周和8周后测量ghrelin和PYY的血浆浓度以及能量摄入和体重。两个治疗期的体重增加（体重：0.40 ± 0.94 kg，P < 0.001;安慰剂：0.66 ± 0.87 kg，P = 0.018），治疗之间没有显著差异。能量摄入无显著差异（P = 0.634）。PYY在雌马酚治疗期间显著增加（51 ± 2 pmol/L vs. 55 ± 2 pmol/L），但在安慰剂期间未显著增加（52 ± 3 pmol/L vs. 50 ± 2 pmol/L）（治疗差异P = 0.010，与雌马酚产生无关）。雌马酚产生者的基线血浆ghrelin（110 ± 16 pmol/L）显著低于雌马酚非产生者（162 ± 17 pmol/L; P = 0.025）。补充大豆蛋白8周并没有显著降低能量摄入或体重，即使在大豆蛋白治疗期间血浆PYY增加。Ghrelin仍然不受Escherichia coli治疗的影响。一个更大、更严格的食欲实验可能会发现，在重复消费后，能量摄入的差异较小。然而，本研究的结果并不表明增加的PYY在体重调节中起主要作用，至少在健康的绝经后妇女中是如此。
Soy isoflavones show structural and functional similarities to estradiol. Available data indicate that estradiol and estradiol-like components may interact with gut "satiety hormones" such as peptide YY (PYY) and ghrelin, and thus influence body weight. In a randomized, double-blind, placebo-controlled, cross-over trial with 34 healthy postmenopausal women (59 ± 6 years, BMI: 24.7 ± 2.8 kg/m2), isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1) or non-isoflavone-enriched control bars were consumed for 8 weeks (wash-out period: 8-weeks). Seventeen of the subjects were classified as equol producers. Plasma concentrations of ghrelin and PYY, as well as energy intake and body weight were measured at baseline and after four and eight weeks of each intervention arm. Body weight increased in both treatment periods (isoflavone: 0.40 ± 0.94 kg, P < 0.001; placebo: 0.66 ± 0.87 kg, P = 0.018), with no significant difference between treatments. No significant differences in energy intake were observed (P = 0.634). PYY significantly increased during isoflavone treatment (51 ± 2 pmol/L vs. 55 ± 2 pmol/L), but not during placebo (52 ± 3 pmol/L vs. 50 ± 2 pmol/L), (P = 0.010 for treatment differences, independent of equol production). Baseline plasma ghrelin was significantly lower in equol producers (110 ± 16 pmol/L) than in equol non-producers (162 ± 17 pmol/L; P = 0.025). Soy isoflavone supplementation for eight weeks did not significantly reduce energy intake or body weight, even though plasma PYY increased during isoflavone treatment. Ghrelin remained unaffected by isoflavone treatment. A larger and more rigorous appetite experiment might detect smaller differences in energy intake after isoflavone consumption. However, the results of the present study do not indicate that increased PYY has a major role in the regulation of body weight, at least in healthy postmenopausal women.